These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24078271)

  • 1. The aggressive peripheral T-cell lymphomas: 2013.
    Armitage JO
    Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
    Armitage JO
    Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aggressive peripheral T-cell lymphomas: 2015.
    Armitage JO
    Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The aggressive peripheral T-cell lymphomas: 2017.
    Armitage JO
    Am J Hematol; 2017 Jul; 92(7):706-715. PubMed ID: 28516671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
    Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
    Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
    Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
    Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
    Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
    Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
    Ngu HS; Savage KJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
    Liang X; Guo L; Hu X; Li S; Wen S
    Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
    Rüdiger T; Weisenburger DD; Anderson JR; Armitage JO; Diebold J; MacLennan KA; Nathwani BN; Ullrich F; Müller-Hermelink HK;
    Ann Oncol; 2002 Jan; 13(1):140-9. PubMed ID: 11863096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas.
    Karakas T; Bergmann L; Stutte HJ; Jäger E; Knuth A; Weidmann E; Mitrou PS; Hoelzer D
    Leuk Lymphoma; 1996 Dec; 24(1-2):121-9. PubMed ID: 9049968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma.
    Melnyk A; Rodriguez A; Pugh WC; Cabannillas F
    Blood; 1997 Jun; 89(12):4514-20. PubMed ID: 9192775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
    Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
    Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry.
    Kida S; Fuji S; Morishima T; Nakata K; Miyashiro I; Ishikawa J
    Int J Hematol; 2021 Aug; 114(2):246-251. PubMed ID: 33864237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.